Immuneering Corporation Increase (Decrease) in Prepaid Expense and Other Assets
Immuneering Corporation (IMRX) reported Increase (Decrease) in Prepaid Expense and Other Assets of $4.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-05
- Immuneering Corporation increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $3.49M.
- Immuneering Corporation increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $1.18M.
- Immuneering Corporation increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $1.41M.
- Immuneering Corporation increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $168.82K, a 73.81% decline year-over-year.
- Immuneering Corporation increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$491.84K, a 2078.03% decline from fiscal 2024.
- Immuneering Corporation increase (decrease) in prepaid expense and other assets for fiscal 2024 was $24.86K, a 85.60% decline from fiscal 2023.
- Immuneering Corporation increase (decrease) in prepaid expense and other assets for fiscal 2023 was $172.66K, a 39.28% decline from fiscal 2022.
- Immuneering Corporation increase (decrease) in prepaid expense and other assets for fiscal 2022 was $284.35K, a 88.20% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.68M 10-Q · filed 2026-08-05 | $6.09M derived: sum of 3 quarters · filed 2026-08-05 | $6.26M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.18M 10-Q · filed 2026-05-15 | $2.59M derived: sum of 2 quarters · filed 2026-05-15 | $2.76M derived: sum of 3 quarters · filed 2026-05-15 | $1.79M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $1.58M derived: sum of 2 quarters · filed 2026-03-06 | $610.55K derived: sum of 3 quarters · filed 2026-08-05 | -$491.84K 10-K · filed 2026-03-06 |
| 2025-09-30 | $168.82K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$801.71K derived: sum of 2 quarters · filed 2026-08-05 | -$1.90M 10-Q · filed 2025-11-12 | -$3.06M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$970.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$2.07M 10-Q · filed 2026-08-05 | -$3.23M derived: sum of 3 quarters · filed 2026-08-05 | -$2.59M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$1.10M 10-Q · filed 2026-05-15 | -$2.26M derived: sum of 2 quarters · filed 2026-05-15 | -$1.62M derived: sum of 3 quarters · filed 2026-05-15 | -$828.63K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$514.37K derived: sum of 2 quarters · filed 2026-03-06 | $273.76K derived: sum of 3 quarters · filed 2026-03-06 | $24.86K 10-K · filed 2026-03-06 |
| 2024-09-30 | $644.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.43M derived: sum of 2 quarters · filed 2025-11-12 | $1.18M 10-Q · filed 2025-11-12 | $1.23M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $788.13K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $539.24K 10-Q · filed 2025-08-13 | $581.18K derived: sum of 3 quarters · filed 2025-08-13 | $1.40M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$248.90K 10-Q · filed 2025-05-05 | -$206.95K derived: sum of 2 quarters · filed 2025-05-05 | $611.54K derived: sum of 3 quarters · filed 2025-05-05 | $436.66K derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $41.95K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $860.44K derived: sum of 2 quarters · filed 2025-03-20 | $685.56K derived: sum of 3 quarters · filed 2025-03-20 | $172.66K 10-K · filed 2025-03-20 |
| 2023-09-30 | $818.49K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $643.61K derived: sum of 2 quarters · filed 2024-11-13 | $130.71K 10-Q · filed 2024-11-13 | $581.47K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$174.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$687.78K 10-Q · filed 2024-08-06 | -$237.02K derived: sum of 3 quarters · filed 2024-08-06 | $1.62M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$512.90K 10-Q · filed 2024-05-07 | -$62.14K derived: sum of 2 quarters · filed 2024-05-07 | $1.80M derived: sum of 3 quarters · filed 2024-05-07 | $1.18M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $450.76K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $2.31M derived: sum of 2 quarters · filed 2024-03-01 | $1.69M derived: sum of 3 quarters · filed 2024-03-01 | $284.35K 10-K · filed 2024-03-01 |
| 2022-09-30 | $1.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.24M derived: sum of 2 quarters · filed 2023-11-09 | -$166.41K 10-Q · filed 2023-11-09 | -$879.97K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$617.28K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$2.03M 10-Q · filed 2023-08-03 | -$2.74M derived: sum of 3 quarters · filed 2023-08-03 | -$173.04K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$1.41M 10-Q · filed 2023-05-04 | -$2.12M derived: sum of 2 quarters · filed 2023-05-04 | $444.24K derived: sum of 3 quarters · filed 2023-05-04 | $384.32K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$713.56K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $1.85M derived: sum of 2 quarters · filed 2023-03-06 | $1.79M derived: sum of 3 quarters · filed 2023-03-06 | $2.41M 10-K · filed 2023-03-06 |
| 2021-09-30 | $2.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $2.51M derived: sum of 2 quarters · filed 2022-11-10 | $3.12M 10-Q · filed 2022-11-10 | $3.05M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$59.92K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $555.73K 10-Q · filed 2022-08-10 | $485.68K derived: sum of 3 quarters · filed 2022-08-10 | $237.96K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $615.64K 10-Q · filed 2022-05-10 | $545.59K derived: sum of 2 quarters · filed 2022-05-10 | $297.88K derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$70.05K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$317.77K derived: sum of 2 quarters · filed 2022-03-10 | $69.74K 10-K · filed 2022-03-10 | |
| 2020-09-30 | -$247.72K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $139.79K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $387.51K 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |